NMTC NeuroOne (NMTC) Q3 FY26 earnings call
NeuroOne delivered a strong quarter with double-digit revenue growth and significant gross margin expansion, driven by its OneRF Brain Ablation System. The company achieved a major milestone with ISO 13485 certification, opening doors for international expansion with Zimmer Biomet and independent partners. While manufacturing delays impacted full-year revenue recognition, the company is addressing this with plans for a second manufacturing site and continues to advance its StereoCED drug delivery system and BVNA back pain program through strategic collaborations and regulatory pathways.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.